SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-09-215910
Filing Date
2009-10-28
Accepted
2009-10-28 13:29:29
Documents
7
Period of Report
2009-10-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d8k.htm 8-K 36969
2 AGREEMENT AND PLAN OF MERGER dex101.htm EX-10.1 376017
3 FORM OF ROCHE CONTINGENT VALUE RIGHTS AGREEMENT dex102.htm EX-10.2 95312
4 FORM OF TR BETA CONTINGENT VALUE RIGHTS AGREEMENT dex103.htm EX-10.3 100766
5 FORM OF GLUCAGON CONTINGENT VALUE RIGHTS AGREEMENT dex104.htm EX-10.4 101302
6 FORM OF GENERAL CONTINGENT VALUE RIGHTS AGREEMENT dex105.htm EX-10.5 122251
7 FORM OF VOTING AGREEMENT dex106.htm EX-10.6 42788
  Complete submission text file 0001193125-09-215910.txt   876932
Mailing Address 10275 SCIENCE CENTER DRIVE SAN DIEGO CA 92121-1117
Business Address 10275 SCIENCE CENTER DRIVE SAN DIEGO CA 92121-1117 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 091141191
SIC: 2834 Pharmaceutical Preparations